Asuragen, Inc. Announces Launch Of Highly Sensitive CE-IVD BCR-ABL Assay At The European Hematology Association Annual Congress

AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc. announced today the commercial launch of its CE-IVD Quantidex™ BCR-ABL IS CMR Kit for monitoring BCR-ABL1 transcript levels in patients with Chronic Myeloid Leukemia (CML). Asuragen will introduce the assay at the European Hematology Association (EHA) 20th Annual Congress in Vienna, Austria, June 11-14th, 2015. The Quantidex™ BCR-ABL IS CMR Kit represents an improvement to existing tests by attaining a sensitivity of MR4.7 (0.002% IS) while also allowing direct reporting on the International Scale (IS).

Help employers find you! Check out all the jobs and post your resume.